ImmunityBio Inc.: Next-Generation Immunotherapies - D. Boral Capital Sees 259% Price Potential
Reading Time: 3 minutes
Revolutionary Immune Modulation as a Core Competence ImmunityBio Inc. (IBRX) has transformed from a classic biotech research company into a commercial player in the next-generation immunotherapy sector. The company's core approach fundamentally differs from traditional chemotherapy or simple checkpoint inhibitors by aiming to comprehensively "orchestrate” the patient’s immune system. The technological platform is based on activating both the innate immune system (Natural Killer Cells, NK cells) and the adaptive immune system (T cells). The...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
